Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease

Inclusion Criteria:

1. Male and female patients, treatment naïve, and aged between 18 and 60 years included

2. Women of childbearing potential1 (WOCBP) able and willing to use highly effectivemethods of birth control2 per ICH M3 (R2) that result in a low failure rate of lessthan 1% per year when used consistently and correctly for the duration of the studyOR until 3 months after last dose administered.

3. A diagnosis of RRMS according to the 2017 revised diagnostic criteria of McDonald (Thompson, Banwell et al. 2018) within the last 12 months.

4. Disease activity defined as ≥ 1 relapse3 or ≥ 1 new MRI lesion during the last 12months

5. EDSS score ≤ 4.0

6. Absence of comorbidity or drug abuse that preclude study participation

7. Able to complete treatment or follow-up visits in the study (e.g. nocontraindications for MRI or plans of moving)

8. Able to understand written and spoken Norwegian or English

9. Capable of giving signed informed consent as described in Appendix 1.2 whichincludes compliance with the requirements and restrictions listed in the informedconsent form (ICF) and in this protocol.

Exclusion Criteria:

1. Known hypersensitivity or other known side effects for any of the study medications,including co-medications such as high glucocorticosteroids

2. A diagnosis of primary progressive MS according to the revised diagnostic criteriaof McDonald (Thompson, Banwell et al. 2018)

3. A disease course of secondary progressive MS (Lublin, Reingold et al. 2014)

4. Any ongoing infection, including tuberculosis, hepatitis virus or HIV, as well ashepatitis B surface antigen positivity and/or hepatitis C PCR positivity verified atscreening visit.

5. Prior or current psychiatric illness, mental deficiency or cognitive dysfunctioninfluencing the patient ability to make an informed consent or comply with thetreatment and follow-up phases of this protocol.

6. Cardiac insufficiency, cardiomyopathy, significant cardiac dysrhythmia, unstable oradvanced ischemic heart disease (NYHA III or IV)

7. Active malignancy or prior history of malignancy except localized basal cell,squamous skin cancer or carcinoma in situ of the cervix.

8. WBC < 1.5 x 109/L if not caused by a reversible effect of documented ongoingmedication. If WBC < 1.5 x 109/L is caused by a reversible effect of documentedongoing medication the WBC count must be > 1,5 x 109/L before start of studytreatment.

9. Platelet (thrombocyte) count < 100 x 109/L

10. ALAT and/or ASAT more than 2 times the upper normal reference limit (ULN)

11. Serum creatinine > 200 µmol/L

12. Serum bilirubin > ULN

13. Pregnancy or lactating female patients

14. Any disease that can influence the patient safety and compliance, or the evaluationof disability

15. History of serious or life-threatening infusion reaction to ocrelizumab orrituximab, if previously treated with these medications for other diseases than MS

16. Previous use of MS-therapies such as natalizumab, fingolimod, interferons,glatiramer acetate, dimethyl fumarate, teriflunomide, cladribine, rituximab,alemtuzumab, ocrelizumab, hematopoietic stem cell therapy (HSCT) or otherimmunosuppression therapies with long lasting effects, or any other diseasemodifying therapy (DMT) for MS. If any of these medications have been used againstother diseases than MS, patients can be included if the medications have not beenused the previous year before enrollment.

17. Currently enrolled in another investigational device or drug study, or less than 30days since ending another investigational device or drug study (s), or receivingother investigational treatment(s). Patients participating in a purely observationaltrial will not be excluded.

18. Presence of metallic objects implanted in the body, or allergy to MRI contrast thatwould preclude the ability of the patient to safely have MRI exams

19. Current alcohol or drug dependencies